Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147485
Status:
TERMINATED
Last Update Posted:
2008-08-18
First Post:
2005-09-02
Brief Title:
A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 1 Safety Pharmacokinetic And Pharmacodynamic Study Of AG-024322 An Inhibitor Of Cyclin-Dependent Kinase 1 2 And 4 Administered Intravenously Daily For 5 Days Every 3 Weeks To Patients With Advanced Cancer
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See Detailed Description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
AG-024322 may work in cancer by stopping cancer cells from multiplying AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase CDK inhibitors This research study is the first time that AG-024322 will be given to people
Detailed Description:
The study was prematurely discontinued due to the inability of the compound to adequately differentiate from other treatment options in the clinical endpoint and necessary product profile on April 13 2007 Safety profile was not the reason that led to the discontinuation of the program
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None